Drug Profile
Research programme: autoimmune therapies - Genten Therapeutics
Alternative Names: AG 017Latest Information Update: 28 Nov 2022
Price :
$50
*
At a glance
- Originator Genten Therapeutics
- Developer Genten Therapeutics; Precigen Inc
- Class Anti-inflammatories; Bacteria; Peptides
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Coeliac disease
Most Recent Events
- 28 Nov 2022 No recent reports of development identified for preclinical development in Coeliac disease in USA (PO)
- 03 Feb 2020 Intrexon Corporation is now called Precigen Inc
- 19 Aug 2019 ActoBio Therapeutics plans a phase Ib/IIa trial for AG 017 for Coeliac disease in Europe and USA in 2019 (PO, Capsule)